S9346 (prostate cancer trial)
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
NCT00002651
|
| gptkbp:conditionStudied |
prostate cancer
|
| gptkbp:eligibility |
newly diagnosed metastatic prostate cancer
|
| gptkbp:endDate |
2012
|
| gptkbp:enrollment |
3040
|
| gptkbp:fullName |
Southwest Oncology Group S9346 trial
|
| https://www.w3.org/2000/01/rdf-schema#label |
S9346 (prostate cancer trial)
|
| gptkbp:intervention |
androgen deprivation therapy
continuous androgen deprivation intermittent androgen deprivation |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:period |
Phase III
|
| gptkbp:principalInvestigator |
Maha Hussain
|
| gptkbp:publishedIn |
NEJM 2012;366:1205-1215
|
| gptkbp:result |
overall survival
intermittent therapy was not superior to continuous therapy for overall survival |
| gptkbp:sponsor |
gptkb:Southwest_Oncology_Group
|
| gptkbp:startYear |
1995
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:SWOG_Cancer_Research_Network
|
| gptkbp:bfsLayer |
7
|